The Diagnosis and Treatment of Lipid Abnormalities in Pediatric Patients

1.

Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57. https://doi.org/10.1016/S0140-6736(06)68770-9.CrossRefPubMed

2.

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, et al. Heart Disease and Stroke Statistics-2021 update: a Report from the American Heart Association. Circulation. 2021;143:e254–743. https://doi.org/10.1161/CIR.0000000000000950.CrossRefPubMed

3.

Teo KK, Rafiq T. Cardiovascular Risk factors and Prevention: a perspective from developing countries. Can J Cardiol. 2021;37:733–43. https://doi.org/10.1016/j.cjca.2021.02.009.CrossRefPubMed

4.

McGill HC Jr., McMahan CA, Herderick EE, Tracy RE, Malcom GT, Zieske AW, Strong JP. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological determinants of atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000;20:836–45. https://doi.org/10.1161/01.atv.20.3.836.

5.

Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001;104:2815–9.CrossRefPubMed

6.

Gidding SS, McMahan CA, McGill HC, Colangelo LA, Schreiner PJ, Williams OD, Liu K. Prediction of coronary artery calcium in young adults using the pathobiological determinants of atherosclerosis in Youth (PDAY) risk score: the CARDIA study. Arch Intern Med. 2006;166:2341–7. https://doi.org/10.1001/archinte.166.21.2341.CrossRefPubMed

7.

Juonala M, Viikari JS, Ronnemaa T, Marniemi J, Jula A, Loo BM, et al. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol. 2008;28:1012–7. https://doi.org/10.1161/ATVBAHA.108.163329.

8.

Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290:2271–6. https://doi.org/10.1001/jama.290.17.2271.CrossRefPubMed

9.

Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, Lauer RM. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol. 1996;27:277–84. https://doi.org/10.1016/0735-1097(95)00461-0.CrossRefPubMed

10.

McMahan CA, Gidding SS, Viikari JS, Juonala M, Ka ̈ho ̈nen M, Hutri-Ka ̈ho ̈nen N, et al. Association of Pathobiologic determinants of atherosclerosis in youth risk score and 15-year change in risk score with carotid artery intima-media thickness in young adults (from the Cardiovascular Risk in Young Finns Study). Am J Cardiol. 2007;100:1124–9.

11.

Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–6. https://doi.org/10.1056/NEJM199806043382302.

12.

Karagiannis AD, Mehta A, Dhindsa DS, Virani SS, Orringer CE, Blumenthal RS, et al. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021;42(22):2169–2154. https://doi.org/10.1093/eurheartj/ehaa1080.

13.

LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am J Cardiol. 2013;111:1221–9. https://doi.org/10.1016/j.amjcard.2012.12.052.CrossRefPubMed

14.

Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90. https://doi.org/10.1016/S0140-6736(12)60367-5.CrossRef

15.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003;92:152–60. https://doi.org/10.1016/s0002-9149(03)00530-7.CrossRefPubMed

16.

Juonala M, Viikari JS, Raitakari OT. Main findings from the prospective Cardiovascular Risk in Young Finns Study. Curr Opin Lipidol. 2013;24:64–57. https://doi.org/10.1097/MOL.0b013e32835a7ed4.CrossRefPubMed

17.

McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. 2002;105:2712–8. https://doi.org/10.1161/01.cir.0000018121.67607.ce.

18.

de Jongh S, Lilien MR, op’t Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117–21. https://doi.org/10.1016/s0735-1097(02)02593-7.CrossRefPubMed

19.

Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664–8. https://doi.org/10.1161/CIRCULATIONAHA.106.671016.CrossRefPubMed

20.

Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569–78. https://doi.org/10.1001/jama.288.20.2569.CrossRefPubMed

21.

Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart diseases. Arch Intern Med. 2009;169:659–69.CrossRefPubMed

22.

de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J, et al. Cardiovascular Risk Reduction in High-Risk Pediatric patients: A Scientific Statement from the American Heart Association. Circulation. 2019;139:e603–34. https://doi.org/10.1161/CIR.0000000000000618.CrossRefPubMed

23.

Expert Panel on Integrated Guidelines for Cardiovascular, Heart H, Blood L. I. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-256. https://doi.org/10.1542/peds.2009-2107C.

24.

Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G, et al. Life’s essential 8: updating and enhancing the American Heart Association’s construct of Cardiovascular Health: a Presidential Advisory from the American Heart Association. Circulation. 2022;146:e18–43. https://doi.org/10.1161/CIR.0000000000001078.CrossRefPubMedPubMedCentral

25.

Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. J Am Coll Cardiol. 2014;63:2960–84. https://doi.org/10.1016/j.jacc.2013.11.003.CrossRefPubMed

26.

Grundy SM, Arai H, Barter P, Bersot TP, Betteridge DJ, Carmena R, Cuevas A, Davidson MH, Genest J, Kesäniemi YA. An International Atherosclerosis Society Position paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol. 2014;8:29–60.CrossRef

27.

Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, et al. National Lipid Association Recommendations for patient-centered management of Dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1–e122121. https://doi.org/10.1016/j.jacl.2015.09.002.CrossRefPubMed

28.

Baum SJ, Kris-Etherton PM, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, Whelan J, Ramsden CE, Block RC. Fatty acids in cardiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6:216–34. https://doi.org/10.1016/j.jacl.2012.04.077.CrossRefPubMedPubMedCentral

29.

Cai L, Wu Y, Cheskin LJ, Wilson RF, Wang Y. Effect of childhood obesity prevention programmes on blood lipids: a systematic review and meta-analysis. Obes Reviews: Official J Int Association Study Obes. 2014;15:933–44. https://doi.org/10.1111/obr.12227.CrossRef

30.

Cesa CC, Sbruzzi G, Ribeiro RA, Barbiero SM, de Oliveira Petkowicz R, Eibel B, Machado NB, Marques R, Tortato G, dos Santos TJ, et al. Physical activity and cardiovascular risk factors in children: meta-analysis of randomized clinical trials. Prev Med. 2014;69:54–62. https://doi.org/10.1016/j.ypmed.2014.08.014.CrossRefPubMed

31.

Escalante Y, Saavedra JM, Garcia-Hermoso A, Dominguez AM. Improvement of the lipid profile with exercise in obese children: a systematic review. Prev Med. 2012;54:293–301. https://doi.org/10.1016/j.ypmed.2012.02.006.CrossRefPubMed

32.

Ho M, Garnett SP, Baur L, Burrows T, Stewart L, Neve M, Collins C. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. Pediatrics. 2012;130:e1647–1671. https://doi.org/10.1542/peds.2012-1176.CrossRefPubMed

33.

Andersen LB, Riddoch C, Kriemler S, Hills AP. Physical activity and cardiovascular risk factors in children. Br J Sports Med. 2011;45:871–6. https://doi.org/10.1136/bjsports-2011-090333.CrossRefPubMed

34.

Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483–92. https://doi.org/10.1056/NEJMoa020194.CrossRefPubMed

35.

Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in children and adolescents: a meta-analysis of randomized controlled trials. Atherosclerosis. 2007;191:447–53. https://doi.org/10.1016/j.atherosclerosis.2006.04.019.CrossRefPubMed

36.

Stoedefalke K. Effects of exercise training on blood lipids and lipoproteins in children and adolescents. J Sports Sci Med. 2007;6:313–8.PubMedPubMedCentral

37.

Watts K, Jones TW, Davis EA, Green D. Exercise training in obese children and adolescents: current concepts. Sports Med (Auckland NZ). 2005;35:375–92. https://doi.org/10.2165/00007256-200535050-00002.CrossRef

38.

Bouchard C, An P, Rice T, Skinner JS, Wilmore JH, Gagnon J, et al. Familial aggregation of V̇O(2max) response to exercise training: results from the HERITAGE Family Study. J Appl Physiol. 1999;87(3):1008–1003

39.

Rowland TW, Martel L, Vanderburgh P, Manos T, Charkoudian N. The influence of short-term aerobic training on blood lipids in healthy 10–12 year old children. Int J Sports Med. 1996;17:487–92. https://doi.org/10.1055/s-2007-972883.CrossRefPubMed

40.

Kang HS, Gutin B, Barbeau P, Owens S, Lemmon CR, Allison J, Litaker MS, Le NA. Physical training improves insulin resistance syndrome markers in obese adolescents. Med Sci Sports Exerc. 2002;34:1920–7. https://doi.org/10.1097/00005768-200212000-00010.CrossRefPubMed

41.

Tolfrey K, Jones AM, Campbell IG. The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents. Sports medicine (Auckland, NZ). 2000;29:99–112. https://doi.org/10.2165/00007256-200029020-00003.

42.

Obarzanek E, Hunsberger SA, Van Horn L, Hartmuller VV, Barton BA, Stevens VJ, et al. Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics. 1997;100:51–9. https://doi.org/10.1542/peds.100.1.51.

43.

Obarzanek E, Kimm SY, Barton BA, Van Horn LL, Kwiterovich PO Jr., Simons-Morton DG, Hunsberger SA, Lasser NL, Robson AM, Franklin FA Jr., et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the dietary intervention study in children (DISC). Pediatrics. 2001;107:256–64. https://doi.org/10.1542/peds.107.2.256.

44.

Simell O, Niinikoski H, Ronnemaa T, Lapinleimu H, Routi T, Lagstrom H, Salo P, Jokinen E, Viikari J. Special Turku coronary risk factor intervention project for babies (STRIP). Am J Clin Nutr. 2000;72:S1316–31. https://doi.org/10.1093/ajcn/72.5.1316s.CrossRef

45.

Niinikoski H, Pahkala K, Ala-Korpela M, Viikari J, Ronnemaa T, Lagstrom H, Jokinen E, Jula A, Savolainen MJ, Simell O, et al. Effect of repeated dietary counseling on serum lipoproteins from infancy to adulthood. Pediatrics. 2012;129:e704–713. https://doi.org/10.1542/peds.2011-1503.CrossRefPubMed

46.

U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th Edition. December 2015. http://health.gov/dietaryguidelines/2015/guidelines/.

47.

Braamskamp MJ, Hutten BA, Wiegman A, Kastelein JJ. Management of hypercholesterolemia in children. Paediatr Drugs. 2014;16:105–14. https://doi.org/10.1007/s40272-013-0060-2.CrossRefPubMed

48.

Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57. https://doi.org/10.1056/NEJM199811053391902.CrossRef

49.

Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, Kastelein JJP, Hutten BA. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381:1547–56. https://doi.org/10.1056/NEJMoa1816454.CrossRefPubMed

50.

Saxon DR, Eckel RH. Statin intolerance: a literature review and management strategies. Prog Cardiovasc Dis. 2016;59:153–64. https://doi.org/10.1016/j.pcad.2016.07.009.CrossRefPubMed

51.

Johnson PK, Mendelson MM, Baker A, Ryan HH, Warren S, Graham D, Griggs SS, Desai NK, Yellen E, Buckley L, et al. Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice. J Pediatr. 2017;185:94–e9891. https://doi.org/10.1016/j.jpeds.2017.02.047.CrossRefPubMedPubMedCentral

52.

Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10. https://doi.org/10.1161/ATVBAHA.107.145151.CrossRefPubMed

53.

Kellick KA. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol. 2014;8(3 Supp):S30-46

54.

Bays H, Cohen DE, Chalasani N, Harrison SA. The National Lipid Association’s Statin Safety Task F. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S47–57. https://doi.org/10.1016/j.jacl.2014.02.011.CrossRefPubMed

55.

Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24:1359–62. https://doi.org/10.1185/030079908x292029.CrossRefPubMed

56.

Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123–30. https://doi.org/10.1016/j.amjcard.2012.12.037.CrossRefPubMed

57.

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64. https://doi.org/10.1001/jama.2011.860.CrossRefPubMed

58.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42. https://doi.org/10.1016/S0140-6736(09)61965-6.CrossRefPubMed

59.

Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25:1131–49. https://doi.org/10.1002/pds.4020.CrossRefPubMed

60.

Mora S, Ridker PM. Justification for the Use of statins in primary Prevention: an intervention trial evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97:A33–41. https://doi.org/10.1016/j.amjcard.2005.11.014.CrossRef

61.

Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116:682–8. https://doi.org/10.1542/peds.2004-2090.CrossRefPubMed

62.

Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64:496–509. https://doi.org/10.1111/j.1365-2125.2007.02905.x.CrossRefPubMedPubMedCentral

63.

Kusters DM, Caceres M, Coll M, Cuffie C, Gagne C, Jacobson MS, Kwiterovich PO, Lee R, Lowe RS, Massaad R et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166:1377–1384 e1371-1373. https://doi.org/10.1016/j.jpeds.2015.02.043.

64.

Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–41. https://doi.org/10.1016/s0195-668x(02)00807-2.CrossRefPubMed

65.

Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, Ezetimibe Study G. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–7. https://doi.org/10.1016/s0002-9149(02)02798-4.CrossRefPubMed

66.

Yeste D, Chacon P, Clemente M, Albisu MA, Gussinye M, Carrascosa A. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metabolism: JPEM. 2009;22:487–92. https://doi.org/10.1515/jpem.2009.22.6.487.CrossRef

67.

Clauss S, Wai KM, Kavey RE, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869–72. https://doi.org/10.1016/j.jpeds.2008.12.044.CrossRefPubMed

68.

Feingold KR. Cholesterol lowering drugs [Updated 2024 Feb 12]. In: Feingold KR, Anawalt B, Blackman MR, editors. Endotext. South Dartmouth (MA): MDText.com; 2021.

69.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489.CrossRefPubMed

70.

Gagne C, Gaudet D, Bruckert E, Ezetimibe Study G. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–75. https://doi.org/10.1161/01.cir.0000018744.58460.62.CrossRefPubMed

71.

McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74–80. https://doi.org/10.1016/S0022-3476(03)00186-0.CrossRefPubMed

72.

European Association for, Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818. https://doi.org/10.1093/eurheartj/ehr158.CrossRef

73.

Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27. https://doi.org/10.2147/VHRM.S33664.CrossRefPubMedPubMedCentral

74.

Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin. 2005;21:333–8. https://doi.org/10.1185/030079905X28872.CrossRefPubMed

75.

Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2007;3:441–50. https://doi.org/10.1517/17425255.3.3.441.CrossRefPubMed

76.

Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther. 2003;25:2352–87. https://doi.org/10.1016/s0149-2918(03)80281-3.CrossRefPubMed

77.

Escola-Gil JC, Quesada H, Julve J, Martin-Campos JM, Cedo L, Blanco-Vaca F. Sitosterolemia: diagnosis, investigation, and management. Curr Atheroscler Rep. 2014;16:424. https://doi.org/10.1007/s11883-014-0424-2.CrossRefPubMed

78.

Rocha VZ, Tada MT, Chacra APM, Miname MH, Mizuta MH. Update on sitosterolemia and atherosclerosis. Curr Atheroscler Rep. 2023;25:181–7. https://doi.org/10.1007/s11883-023-01092-4.CrossRefPubMed

79.

Othman RA, Myrie SB, Mymin D, Merkens LS, Roullet JB, Steiner RD, Jones PJ. Ezetimibe reduces plant sterol accumulation and favorably increases platelet count in sitosterolemia. J Pediatr. 2015;166:125–31. https://doi.org/10.1016/j.jpeds.2014.08.069.CrossRefPubMed

80.

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, et al. Bempedoic Acid and Cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353–64. https://doi.org/10.1056/NEJMoa2215024.CrossRefPubMed

81.

Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of Bempedoic Acid vs Placebo added to maximally tolerated statins on Low-Density Lipoprotein Cholesterol in patients at High Risk for Cardiovascular Disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322:1780–8. https://doi.org/10.1001/jama.2019.16585.CrossRefPubMedPubMedCentral

82.

Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008;49(6):1156–1152

83.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664.CrossRefPubMed

84.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107. https://doi.org/10.1056/NEJMoa1801174.CrossRefPubMed

85.

Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, et al. Evolocumab in Pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383:1317–27. https://doi.org/10.1056/NEJMoa2019910.CrossRefPubMed

86.

Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56. https://doi.org/10.1056/NEJMoa061189.CrossRefPubMed

87.

Berberich AJ, Hegele RA. Expert Opinion on Pharmacotherapy Lomitapide for the treatment of hypercholesterolemia Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18.

88.

Raal FJ. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016;10(4):869–860.

89.

Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, Baker BF, Fuhr R, Wedel MK, Kastelein JJ. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650–9. https://doi.org/10.1093/eurheartj/ehr148.CrossRefPubMed

90.

Cartier JL, Goldberg AC. Familial hypercholesterolemia: advances in Recognition and Therapy. Prog Cardiovasc Dis. 2016;59:125–34. https://doi.org/10.1016/j.pcad.2016.07.006.CrossRefPubMedPubMedCentral

91.

Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, Srinivasan S, Baker-Smith C, Baum S, Brothers JA, et al. Evinacumab for Pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149:343–53. https://doi.org/10.1161/CIRCULATIONAHA.123.065529.CrossRefPubMed

92.

Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011;5:76–81. https://doi.org/10.1016/j.jacl.2011.01.005.CrossRefPubMed

93.

Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Practice: Official J Am Coll Endocrinol Am Association Clin Endocrinologists. 2010;16:617–28. https://doi.org/10.4158/EP10129.OR.CrossRef

94.

Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015;37:2153–79. https://doi.org/10.1016/j.clinthera.2015.09.001.CrossRefPubMed

95.

Ross S, D’Mello M, Anand SS, Eikelboom J, Consortium CAD, Stewart AF, Samani NJ, Roberts R, Pare G. Effect of bile acid sequestrants on the risk of Cardiovascular events: a mendelian randomization analysis. Circ Cardiovasc Genet. 2015;8:618–27. https://doi.org/10.1161/CIRCGENETICS.114.000952.CrossRefPubMed

96.

Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal medications in cardiovascular medicine. J Am Coll Cardiol. 2017;69(9)

97.

Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Chinese Coronary Secondary Prevention, Study G, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–93. https://doi.org/10.1016/j.amjcard.2008.02.056.CrossRefPubMed

98.

Cicero AFG, Fogacci F, Zambon A. Red yeast rice for hypercholesterolemia: JACC focus seminar. J Am Coll Cardiol. 2021;77:620–8. https://doi.org/10.1016/j.jacc.2020.11.056.CrossRefPubMed

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

The Diagnosis and Treatment of Lipid Abnormalities in Pediatric Patients

Abstract

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Use of Dupilumab in Pediatric Patients: A Review

Pediatric Environmental Health In Brazil and Latin America: An Appraisal and Future Perspectives

A Narrative Synthesis Review of Legislation Banning Gender-Affirming Care

The Impact of the COVID-19 Pandemic on Adolescent Substance Use

Familial screening for cardiomyopathies and arrhythmias

Advances in fetal heart disease